RPG Life Sciences revenue rises 20% yoy to Rs134.79 crore in Q2FY23; Stock surges 2%

18 Oct 2022 , 09:25 AM

RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2022.

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 21% yoy and by 8% qoq for Q2 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 22.5% to 23.0% Q-o-Q.

Revenue from operations at Rs 134.79 crores registered a growth of 20% yoy and a growth of 5% qoq for Q2 FY23. For H1 FY23 too, the company posted a jump in PBT by 25% yoy and recorded EBITDA margin expansion from 22.6% to 22.8% yoy.

Revenue from operations at Rs263.72 crore registered a growth of 19% yoy for H1 FY23.

Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2 FY23, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 20% and 21% respectively yoy. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% qoq.

Domestic Formulations business has recorded a robust growth both in value and volumes – significantly and consistently ahead of market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake.

At around 9:27 AM, RPG Life Sciences Ltd is currently trading at Rs828.30 per share up by Rs18.35 or 2.27% from its previous closing of Rs809.95 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]